NCT05149300 / 2021-004590-30: COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age |
|
|
| Recruiting | 2a | 28 | US | casirivimab+imdevimab, REGN10933-10987, REGN-COV2, REGEN-COV™, RONAPREVE™ | Regeneron Pharmaceuticals, Regeneron Pharmaceuticals Inc | COVID-19 | 11/22 | 11/22 | | |